HCRTR2
Orexin receptor type 2
As of the edition of 20 October 2026, HCRTR2 (orexin receptor type 2, UniProt O43614) has 15 drugs tested at it and 10 companies on the list, 2 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O43614
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 12
- Disease areas
- Mental health; Nervous system; Lungs and airways; Chemically induced; Digestive system; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 236
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 2 |
| Went quiet | 5 |
| Stopped | 3 |
| Total | 15 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Suvorexant | Marketed | Phase 4 | Ends 2029 |
| Lemborexant | Marketed | Phase 4 | Ends 2031 |
| Daridorexant | Marketed | Phase 4 | Ends 2034 |
| Seltorexant | Active | Phase 3 | none listed |
| Orn-0829 hydrate | Marketed | Phase 3 | none listed |
| Danavorexton | Stopped | Phase 2 | none listed |
| Almorexant | Went quiet | Phase 3 | none listed |
| SB-649868 | Went quiet | Phase 2 | none listed |
| TAK-994 | Stopped | Phase 2 | none listed |
| Filorexant | Stopped | Phase 2 | none listed |
| TAK-861 | Active | Phase 3 | none listed |
| MK-1064 | Went quiet | Phase 1 | none listed |
12 of 15 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 4 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Idorsia Pharmaceuticals | Route B |
| Merck & Co. | Route B |
| Eisai | Route B |
The other 7 companies at HCRTR2
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at HCRTR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.